Literature DB >> 28480774

Endoscopic management of upper-tract urothelial carcinoma.

Jay D Raman1, Rosa Park1.   

Abstract

INTRODUCTION: Radical nephroureterectomy with an ipsilateral bladder cuff is the referent standard for management of muscle-invasive, high-grade, or bulky upper-tract urothelial carcinoma (UTUC). Nonetheless, certain patients with UTUC have imperative or elective indications for kidney preservation thereby lending to more conservative strategies for management of this disease. Areas covered: A review of the PubMED and Medline databases was performed to identify original scientific and review articles discussing retrograde ureteroscopic or percutaneous antegrade resection of UTUC tumors published between 1995 and 2016. Comparative studies with radical nephroureterectomy were also included. Expert commentary: Endoscopic ablative treatments via retrograde or antegrade approaches may appropriately treat small, solitary, and low risk UTUC tumors. Recurrences in the ipsilateral upper-tract and bladder distal to the original tumor can occur following nephron-sparing treatments and therefore a vigilant surveillance program with a compliant patient is essential when pursuing this treatment approach.

Entities:  

Keywords:  Urothelial cancer; endoscopic ablation; kidney preservation; percutaneous; ureteroscopy

Mesh:

Year:  2017        PMID: 28480774     DOI: 10.1080/14737140.2017.1326823

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  2 in total

1.  A Novel Preoperative Prediction Model Based on Deep Learning to Predict Neoplasm T Staging and Grading in Patients with Upper Tract Urothelial Carcinoma.

Authors:  Yuhui He; Wenzhi Gao; Wenwei Ying; Ninghan Feng; Yang Wang; Peng Jiang; Yanqing Gong; Xuesong Li
Journal:  J Clin Med       Date:  2022-09-30       Impact factor: 4.964

Review 2.  Nephron-sparing approaches in the management of upper tract urothelial carcinoma: indications and clinical outcomes.

Authors:  Young Hwii Ko
Journal:  Transl Cancer Res       Date:  2020-10       Impact factor: 1.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.